• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


South Korea-Based UNDBIO Establishes Rockville, Maryland, Operations

UNDBIO, a Korean pharmaceutical company that provides diabetic care solutions, will open its new U.S. research and development headquarters in Montgomery County, Maryland.

The company leased a 25,000-square-foot facility where it will build out a state-of-the-art laboratory and R&D operations. Located at 12441 Parklawn Drive, UNDBIO is expected to begin working on its insulin product next year.

“I am happy to establish our relationship with the state of Maryland to undertake the research and development required to produce affordable insulin and insulin analogues for the diabetic population around the globe,” UNDBIO’s Chairman Jun Yong-soo said . “We look forward to developing high paying biotech jobs for Maryland, and would welcome other partners into our global insulin project.”

UNDBIO is adopting lean models of Insulin, Insulin Analogs and other biosimilars development and rapidly evolving technologies such as data platforms and data analytics to help reduce the residual uncertainties that require new biosimilars to be subjected to human trials.

“Maryland is proud to be home to hundreds of life sciences companies that set the bar for biotechnology innovation and fuel our region’s innovative economy, and we are excited to welcome the life-saving work of UNDBIO to Rockville,” noted Governor Larry Hogan. “This is yet another shining example that Maryland is open for business and further evidence of our state’s special bond with the Republic of Korea.”

Exclusive Research